Bessemer Group Inc. Has $177.41 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Bessemer Group Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 582,269 shares of the company's stock after purchasing an additional 6,225 shares during the period. Bessemer Group Inc. owned approximately 1.93% of Medpace worth $177,411,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. increased its position in shares of Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares during the period. Proficio Capital Partners LLC boosted its stake in Medpace by 34,497.4% during the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock worth $80,575,000 after buying an additional 241,827 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Medpace during the fourth quarter worth $78,144,000. Norges Bank bought a new stake in Medpace in the 4th quarter valued at $69,859,000. Finally, GW&K Investment Management LLC increased its holdings in Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after buying an additional 133,379 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

Shares of NASDAQ MEDP traded up $3.89 during mid-day trading on Friday, hitting $310.69. 677,983 shares of the stock were exchanged, compared to its average volume of 373,382. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The stock's fifty day simple moving average is $300.94 and its two-hundred day simple moving average is $320.24. The company has a market cap of $8.93 billion, a P/E ratio of 23.72, a PEG ratio of 5.54 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 54.36% and a net margin of 19.31%. The business had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same period in the prior year, the company earned $3.20 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MEDP shares. Mizuho reduced their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Truist Financial dropped their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday, April 23rd. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Robert W. Baird lowered their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Twelve analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $344.82.

Insider Transactions at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.